on Tacalyx GmbH
Tacalyx Appoints Jean Engela as CEO to Drive Growth
Tacalyx GmbH, a biotech company based in Berlin, has appointed Jean Engela as its new Chief Executive Officer. Engela brings over two decades of experience in drug research and development. Previously, he was CEO at NBE Therapeutics and an Executive Drug Development Leader at Boehringer Ingelheim. His role will focus on guiding Tacalyx as it transitions into a clinical-stage company.
With the appointment, Tacalyx's former CEO, Dr. Peter Sondermann, will now serve as Chief Scientific Officer. Chairman Klaus Schollmeier expressed gratitude for Sondermann’s contributions while highlighting Engela's leadership strengths.
Under Engela, Tacalyx plans to enhance its targeted therapeutic developments for cancer treatment, including the promising TCX-201 compound poised for IND-enabling studies.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Tacalyx GmbH news